Please ensure Javascript is enabled for purposes of website accessibility

Illumina Adds Former FDA Commissioner Scott Gottlieb to Its Board of Directors

By Brian Orelli, PhD – Updated Feb 10, 2020 at 1:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The move should be helpful as the DNA-sequencing specialist develops diagnostic tests that require his former agency's approval.

As Illumina (ILMN -4.37%) moves more into the clinical diagnosis space, the DNA-sequencing specialist has made a big addition to its board of directors: Scott Gottlieb, a former commissioner of the Food and Drug Administration. Gottlieb is currently a special partner at the venture capital firm New Enterprise Associates as well as a resident fellow at  the American Enterprise Institute, a public policy think tank.

Scott Gottlieb

Scott Gottlieb. Image source: Business Wire.

Illumina wanted Gottlieb so badly, it expanded its board to 10 members in order to accommodate the former FDA chief. Illumina isn't the first healthcare company to snag Gottlieb. He also serves on the boards of Pfizer, privately held Aetion, and a think tank called FasterCures.

For years, Illumina has sold DNA-sequencing machines and reagents primarily to researchers, but the company has steadily moved in the direction of using the technique for diagnostic purposes.

It still has a stake in spinoff Grail, which is developing blood tests to detect cancer. And last year, Illumina teamed up with Qiagen (QGEN -0.89%), convincing the company to ditch its own next-generation sequencing system in favor of Illumina's systems.

Last month, Illumina struck a 15-year deal with Roche to develop and distribute diagnostic tests on its NextSeq 550Dx System. Roche also has the option to develop tests on future diagnostic sequencing systems that Illumina may develop. Roche will start with developing its Avenio cancer tests for the system, and the duo plan to develop companion diagnostic tests for Roche's drugs. https://www.roche.com/media/releases/med-cor-2020-01-13.htm

As Illumina continues to develop products that will need FDA approval, having Gottlieb on the board to offer insight will certainly be helpful.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Illumina. The Motley Fool recommends Qiagen N.V. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$192.50 (-4.37%) $-8.79
QIAGEN N.V. Stock Quote
QIAGEN N.V.
QGEN
$41.21 (-0.89%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.